Sangamo Therapeutics Inc. logo

Sangamo Therapeutics Inc. (GBY)

Market Closed
11 Jul, 20:00
XSTU XSTU
0. 43
+0
+0.69%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-1.38 Eps
0.42
Previous Close
Day Range
0.43 0.43
Year Range
0.35 3
Want to track GBY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 22 days

Summary

GBY closed yesterday higher at €0.43, an increase of 0.69% from Thursday's close, completing a monthly decrease of -7% or €0.03. Over the past 12 months, GBY stock lost -58.41%.
GBY is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 04, 2025.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

GBY Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Luis Santos - H.C. Wainwright Operator Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call.

Seekingalpha | 2 months ago
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago.

Zacks | 2 months ago
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.

Businesswire | 2 months ago

Sangamo Therapeutics Inc. Dividends

GBY is not paying dividends to its shareholders.

Sangamo Therapeutics Inc. Earnings

6 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
4 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
12 May 2025 Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
11 Mar 2025 Date
-
Cons. EPS
-
EPS
GBY is not paying dividends to its shareholders.
6 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
4 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
12 May 2025 Date
-
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
11 Mar 2025 Date
-
Cons. EPS
-
EPS

Sangamo Therapeutics Inc. (GBY) FAQ

What is the stock price today?

The current price is €0.43.

On which exchange is it traded?

Sangamo Therapeutics Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is GBY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Aug 04, 2025.

Has Sangamo Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Sangamo Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Alexander D. Macrae Ch.B, M.B., MRCP, CEO
XSTU Exchange
US8006771062 ISIN
US Country
183 Employees
- Last Dividend
- Last Split
6 Apr 2000 IPO Date

Overview

Sangamo Therapeutics, Inc. is recognized as a pioneering force in the field of genomic medicine, embarking on the ambitious journey of converting scientific breakthroughs into transformative treatments for individuals afflicted with severe diseases across the United States. Originating in 1995 and undergoing a significant rebranding from Sangamo BioSciences, Inc. to Sangamo Therapeutics, Inc. in January 2017, the company has established its headquarters in Brisbane, California. Through its various collaborative and strategic partnerships with leading entities such as Biogen MA, Inc., Pfizer Inc., and Sanofi S.A., among others, Sangamo stands at the forefront of addressing unmet medical needs by advancing a diverse portfolio of therapeutic candidates through clinical development.

Products and Services

  • ST-920 (Gene Therapy for Fabry Disease)

    ST-920 is advancing through Phase 1/2 clinical trials as a gene therapy candidate aimed at treating Fabry disease, a genetic condition that impairs the body's ability to break down specific fatty substances.

  • TX200 (CAR-Treg Therapy for Kidney Transplantation)

    A cutting-edge chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy, TX200 is in Phase 1/2 clinical study. It is designed for the prevention of immune-mediated rejection in patients undergoing HLA-A2 mismatched kidney transplantation.

  • SB-525 (Gene Therapy for Hemophilia A)

    Targeting the treatment of moderately severe to severe hemophilia A, SB-525 is a gene therapy product in a pivotal Phase 3 clinical trial. This therapy seeks to deliver a functional form of the factor VIII gene to patients, addressing the underlying cause of this bleeding disorder.

  • BIVV003 (Zinc Finger Nuclease Gene-Edited Cell Therapy for Sickle Cell Disease)

    Engaged in the Phase 1/2 PRECIZN-1 clinical study, BIVV003 represents a pioneering approach to treating sickle cell disease. This zinc finger nuclease gene-edited cell therapy aims to correct the genetic mutation in hematopoietic stem cells that causes the disease.

In addition to its clinical-stage candidates, Sangamo Therapeutics, Inc. is also deeply invested in preclinical development efforts. These include CAR-Treg cell therapies targeting autoimmune disorders and groundbreaking genome engineering techniques to tackle neurological diseases, positioning the company as an innovator in genomic medicine.

Contact Information

Address: 501 Canal Blvd
Phone: 510 970 6000